Takeo Nakanishi

Summary

Affiliation: University of Maryland
Country: USA

Publications

  1. ncbi request reprint Drug transporters as targets for cancer chemotherapy
    Takeo Nakanishi
    The Program in Experimental Therapeutics, Marlene and Stewart Greenebaum Cancer Center, School of Medicine, University of Maryland at Baltimore, Baltimore, MD 21201, USA
    Cancer Genomics Proteomics 4:241-54. 2007
  2. ncbi request reprint Novel 5' untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-specific expression, and alternative promoter usage
    Takeo Nakanishi
    The Program in Experimental Therapeutics, Marlene and Stewart Greenebaum Cancer Center Departments of Medicine and Microbiology, University of Maryland School of Medicine, 655 West Baltimore Street, Baltimore, MD 21201, USA
    Cancer Res 66:5007-11. 2006
  3. ncbi request reprint Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients
    Takeo Nakanishi
    Department of Medicine, Division of Hematology Oncology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Clin Cancer Res 9:3320-8. 2003
  4. pmc Identification and characterization of the major alternative promoter regulating Bcrp1/Abcg2 expression in the mouse intestine
    Karthika Natarajan
    Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA
    Biochim Biophys Acta 1809:295-305. 2011
  5. doi request reprint Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias
    Ken Shiozawa
    Program in Experimental Therapeutics, University of Maryland Marlene and Stewart Greenebaum Cancer Center, and Division of Hematology and Oncology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Clin Cancer Res 15:1698-707. 2009
  6. ncbi request reprint Thapsigargin resistance in human prostate cancer cells
    John P O'Neill
    Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, USA
    Cancer 107:649-59. 2006
  7. ncbi request reprint Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression
    Takeo Nakanishi
    Program in Experimental Therapeutics, University of Maryland Marlene and Stewart Greenebaum Cancer Center UMGCC, Baltimore, 21201, USA
    Blood 108:678-84. 2006
  8. pmc A novel xenobiotic responsive element regulated by aryl hydrocarbon receptor is involved in the induction of BCRP/ABCG2 in LS174T cells
    Leslie M Tompkins
    Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD 21201, United States
    Biochem Pharmacol 80:1754-61. 2010
  9. doi request reprint Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: a possible target for combination therapy with anti-proliferative aminopeptidase inhibitors
    Xuetao Fan
    The Program in Experimental Therapeutics, Marlene and Stewart Greenebaum Cancer Center, Departments of Medicine, Pathology and Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, MD, USA
    Biochem Pharmacol 80:811-8. 2010
  10. doi request reprint Impact of breast cancer resistance protein on cancer treatment outcomes
    Douglas D Ross
    University of Maryland Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore VA Medical Center, Baltimore, MD, USA
    Methods Mol Biol 596:251-90. 2010

Collaborators

Detail Information

Publications18

  1. ncbi request reprint Drug transporters as targets for cancer chemotherapy
    Takeo Nakanishi
    The Program in Experimental Therapeutics, Marlene and Stewart Greenebaum Cancer Center, School of Medicine, University of Maryland at Baltimore, Baltimore, MD 21201, USA
    Cancer Genomics Proteomics 4:241-54. 2007
    ..This review will focus on the role of drug transporters in the adaptation and growth of tumors and in their potential usefulness as therapeutic targets in cancer...
  2. ncbi request reprint Novel 5' untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-specific expression, and alternative promoter usage
    Takeo Nakanishi
    The Program in Experimental Therapeutics, Marlene and Stewart Greenebaum Cancer Center Departments of Medicine and Microbiology, University of Maryland School of Medicine, 655 West Baltimore Street, Baltimore, MD 21201, USA
    Cancer Res 66:5007-11. 2006
    ..The exon 1 variation we observe suggests that alternative promoters of the BCRP gene exist...
  3. ncbi request reprint Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients
    Takeo Nakanishi
    Department of Medicine, Division of Hematology Oncology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Clin Cancer Res 9:3320-8. 2003
    ..In vitro cell viability and apoptosis were examined after 24 h exposure to flavopiridol...
  4. pmc Identification and characterization of the major alternative promoter regulating Bcrp1/Abcg2 expression in the mouse intestine
    Karthika Natarajan
    Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA
    Biochim Biophys Acta 1809:295-305. 2011
    ..Furthermore, Bcrp1 E1b mRNA expression is regulated by binding of p-CREB to its cis site on the mouse E1b promoter region...
  5. doi request reprint Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias
    Ken Shiozawa
    Program in Experimental Therapeutics, University of Maryland Marlene and Stewart Greenebaum Cancer Center, and Division of Hematology and Oncology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Clin Cancer Res 15:1698-707. 2009
    ..In this preclinical study, we evaluated combining cytosine arabinoside [1-beta-D-arabinofuranosylcytosine (ara-C)] and/or etoposide with vorinostat for use in the treatment of acute leukemias...
  6. ncbi request reprint Thapsigargin resistance in human prostate cancer cells
    John P O'Neill
    Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, USA
    Cancer 107:649-59. 2006
    ..TG-based prodrugs are being developed for the treatment of prostate cancer (PC). To develop optimal TG-based therapeutics it is important to understand the mechanisms of resistance to TG that may potentially occur in cancer cells...
  7. ncbi request reprint Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression
    Takeo Nakanishi
    Program in Experimental Therapeutics, University of Maryland Marlene and Stewart Greenebaum Cancer Center UMGCC, Baltimore, 21201, USA
    Blood 108:678-84. 2006
    ..These studies show that BCRP causes measurable imatinib resistance, but this effect is attenuated by imatinib-mediated inhibition of BCR-ABL, which in turn downregulates overall BCRP levels posttranscriptionally via the PI3K-Akt pathway...
  8. pmc A novel xenobiotic responsive element regulated by aryl hydrocarbon receptor is involved in the induction of BCRP/ABCG2 in LS174T cells
    Leslie M Tompkins
    Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD 21201, United States
    Biochem Pharmacol 80:1754-61. 2010
    ....
  9. doi request reprint Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: a possible target for combination therapy with anti-proliferative aminopeptidase inhibitors
    Xuetao Fan
    The Program in Experimental Therapeutics, Marlene and Stewart Greenebaum Cancer Center, Departments of Medicine, Pathology and Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, MD, USA
    Biochem Pharmacol 80:811-8. 2010
    ..Our findings indicate that LAT1 expression is increased in human ovarian cancer cell lines; LAT1 may be a target for combination therapy with anti-proliferative aminopeptidase inhibitors to combat ovarian cancer...
  10. doi request reprint Impact of breast cancer resistance protein on cancer treatment outcomes
    Douglas D Ross
    University of Maryland Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore VA Medical Center, Baltimore, MD, USA
    Methods Mol Biol 596:251-90. 2010
    ....
  11. ncbi request reprint Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis
    Takeo Nakanishi
    Greenebaum Cancer Center, University of Maryland School of Medicine, Room 9 045, Bressler Research Building, 655 W Baltimore St, Baltimore, MD 21201, USA
    Mol Pharmacol 64:1452-62. 2003
    ..We conclude that the X. laevis oocyte heterologous expression system is a valid and effective means of studying BCRP function and substrate specificity...
  12. pmc The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells
    Yuexing Zhang
    Greenebaum Cancer Center and Departments of Pathology and Pharmacology, University of Maryland School of Medicine, 655 West Baltimore Street, Baltimore, MD 21201, USA
    Proc Natl Acad Sci U S A 102:9890-5. 2005
    ..These findings suggest that Ebp1 is a previously unrecognized therapeutic target for treatment of hormone refractory prostate cancer...
  13. ncbi request reprint Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial
    Judith E Karp
    University of Maryland Greenebaum Cancer Center, Baltimore, Maryland 2120, USA
    Clin Cancer Res 9:307-15. 2003
    ..trigger apoptosis in fresh acute leukemia; and (b). recruit surviving leukemic cells to a proliferative state, thereby priming such cells for the S-phase-related cytotoxicity of 1-beta-D-arabinofuranosylcytosine (ara-C)...
  14. ncbi request reprint The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells
    Yingqiu Xie
    Department of Pharmacology and Experimental Therapeutics, University of Maryland, Baltimore 21201, USA
    J Biol Chem 283:3349-56. 2008
    ..These findings may provide a potential therapeutic approach by disrupting Pim-1 signaling to reverse BCRP-mediated multidrug resistance...
  15. ncbi request reprint Alterations in the mitochondrial proteome of adriamycin resistant MCF-7 breast cancer cells
    Rachael Strong
    Department of Chemistry and Biochemistry, University of Maryland, College Park, Maryland, USA
    J Proteome Res 5:2389-95. 2006
    ..Eleven mitochondrial proteins were found with abundances altered more than 2-fold. Transcription was evaluated for two of these, using quantitative RT-PCR. Implications of the changes are considered with respect to drug resistance...
  16. ncbi request reprint The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme
    Partha Krishnamurthy
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    J Biol Chem 279:24218-25. 2004
    ..Our findings have implications for the survival of stem cells and tumor cells in hypoxic environments...
  17. ncbi request reprint Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival
    Attaya Suvannasankha
    Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Br J Haematol 127:392-8. 2004
    ..0374) in this small patient population. Poor correlations between mRNA, protein and function indicate the complex biology of BCRP in adult ALL, and the possible correlation of BCRP expression with DFS should be studied in larger series...
  18. ncbi request reprint Transport of D-serine via the amino acid transporter ATB(0,+) expressed in the colon
    Takahiro Hatanaka
    Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, Georgia 30912, USA
    Biochem Biophys Res Commun 291:291-5. 2002
    ..Expression is most predominant in the colon where the transporter is localized to the luminal membrane of colonocytes, making this transporter uniquely suitable for absorption of bacteria-derived D-serine...